Biocardia Stock Performance

BCDA Stock  USD 1.17  0.04  3.54%   
The firm shows a Beta (market volatility) of 0.63, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biocardia's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biocardia is expected to be smaller as well. At this point, Biocardia has a negative expected return of -0.3%. Please make sure to confirm Biocardia's treynor ratio, skewness, rate of daily change, as well as the relationship between the value at risk and accumulation distribution , to decide if Biocardia performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Biocardia has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor
1:15
Dividend Date
2019-06-06
Last Split Date
2024-05-30
1
How BioCardia Inc. stock reacts to bond yields - 2025 Major Catalysts High Accuracy Swing Entry Alerts - B NI V
11/26/2025
2
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
12/01/2025
3
Insider Trading
12/02/2025
4
What MACD trends signal for BioCardia Inc. stock - Rate Hike Scalable Portfolio Growth Ideas - Newser
12/04/2025
5
Acquisition by Slosman Marvin of 12000 shares of Biocardia at 1.37 subject to Rule 16b-3
12/08/2025
6
Acquisition by Peter Altman of 200 shares of Biocardia at 1.37 subject to Rule 16b-3
12/16/2025
7
Acquisition by Peter Altman of 900 shares of Biocardia at 1.3 subject to Rule 16b-3
12/17/2025
8
Is BioCardia Inc. stock protected from inflation - July 2025 Earnings Precise Swing Trade Alerts -
12/19/2025
9
Will BioCardia Inc. stock rally after Fed decisions - July 2025 Weekly Recap Daily Entry Point Alerts - ulpravda.ru
01/08/2026
10
Acquisition by Peter Altman of 600 shares of Biocardia at 1.32 subject to Rule 16b-3
01/20/2026
11
Acquisition by Peter Altman of 300 shares of Biocardia at 1.34 subject to Rule 16b-3
01/21/2026
12
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics
02/03/2026
13
Acquisition by Peter Altman of 5000 shares of Biocardia at 1.13 subject to Rule 16b-3
02/04/2026
14
Acquisition by Peter Altman of 1600 shares of Biocardia at 2.08 subject to Rule 16b-3
02/17/2026
Begin Period Cash Flow1.1 M
Total Cashflows From Investing Activities-6000.00

Biocardia Relative Risk vs. Return Landscape

If you would invest  145.00  in Biocardia on November 27, 2025 and sell it today you would lose (28.00) from holding Biocardia or give up 19.31% of portfolio value over 90 days. Biocardia is currently does not generate positive expected returns and assumes 3.6192% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Biocardia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Biocardia is expected to under-perform the market. In addition to that, the company is 4.73 times more volatile than its market benchmark. It trades about -0.08 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

Biocardia Target Price Odds to finish over Current Price

The tendency of Biocardia Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 1.17 90 days 1.17 
about 90.68
Based on a normal probability distribution, the odds of Biocardia to move above the current price in 90 days from now is about 90.68 (This Biocardia probability density function shows the probability of Biocardia Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Biocardia has a beta of 0.63 suggesting as returns on the market go up, Biocardia average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Biocardia will be expected to be much smaller as well. Additionally Biocardia has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Biocardia Price Density   
       Price  

Predictive Modules for Biocardia

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biocardia. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biocardia's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.061.174.79
Details
Intrinsic
Valuation
LowRealHigh
1.104.728.34
Details
Naive
Forecast
LowNextHigh
0.031.254.87
Details
1 Analysts
Consensus
LowTargetHigh
14.1115.5017.21
Details

Biocardia Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Biocardia is not an exception. The market had few large corrections towards the Biocardia's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biocardia, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biocardia within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.15
β
Beta against Dow Jones0.63
σ
Overall volatility
0.1
Ir
Information ratio -0.05

Biocardia Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biocardia for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biocardia can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Biocardia generated a negative expected return over the last 90 days
Biocardia may become a speculative penny stock
Biocardia has high historical volatility and very poor performance
Biocardia has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 58 K. Net Loss for the year was (7.95 M) with loss before overhead, payroll, taxes, and interest of (5.25 M).
Biocardia currently holds about 8.61 M in cash with (8.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49.
Biocardia has a poor financial position based on the latest SEC disclosures
Roughly 27.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Peter Altman of 1600 shares of Biocardia at 2.08 subject to Rule 16b-3

Biocardia Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Biocardia Stock often depends not only on the future outlook of the current and potential Biocardia's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biocardia's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding2.7 M
Cash And Short Term Investments2.4 M

Biocardia Fundamentals Growth

Biocardia Stock prices reflect investors' perceptions of the future prospects and financial health of Biocardia, and Biocardia fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biocardia Stock performance.

About Biocardia Performance

By analyzing Biocardia's fundamental ratios, stakeholders can gain valuable insights into Biocardia's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biocardia has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biocardia has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 4.69  4.46 
Return On Tangible Assets(2.45)(2.33)
Return On Capital Employed(5.13)(4.88)
Return On Assets(2.45)(2.33)
Return On Equity(10.92)(10.37)

Things to note about Biocardia performance evaluation

Checking the ongoing alerts about Biocardia for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biocardia help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biocardia generated a negative expected return over the last 90 days
Biocardia may become a speculative penny stock
Biocardia has high historical volatility and very poor performance
Biocardia has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 58 K. Net Loss for the year was (7.95 M) with loss before overhead, payroll, taxes, and interest of (5.25 M).
Biocardia currently holds about 8.61 M in cash with (8.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49.
Biocardia has a poor financial position based on the latest SEC disclosures
Roughly 27.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Peter Altman of 1600 shares of Biocardia at 2.08 subject to Rule 16b-3
Evaluating Biocardia's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biocardia's stock performance include:
  • Analyzing Biocardia's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biocardia's stock is overvalued or undervalued compared to its peers.
  • Examining Biocardia's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Biocardia's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biocardia's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Biocardia's stock. These opinions can provide insight into Biocardia's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biocardia's stock performance is not an exact science, and many factors can impact Biocardia's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Biocardia Stock analysis

When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators